

Hui Jing

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3415269/publications.pdf>

Version: 2024-02-01

27
papers

1,922
citations

279701

23
h-index

501076

28
g-index

33
all docs

33
docs citations

33
times ranked

2653
citing authors

#	ARTICLE	IF	CITATIONS
1	The Substrate Specificity of Sirtuins. Annual Review of Biochemistry, 2016, 85, 405-429.	5.0	208
2	Sirtuins in Epigenetic Regulation. Chemical Reviews, 2015, 115, 2350-2375.	23.0	205
3	A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. Cancer Cell, 2016, 29, 297-310.	7.7	183
4	Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions. Cell Research, 2020, 30, 833-853.	5.7	149
5	Sirtuin inhibitors as anticancer agents. Future Medicinal Chemistry, 2014, 6, 945-966.	1.1	148
6	Efficient Demyristoylase Activity of SIRT2 Revealed by Kinetic and Structural Studies. Scientific Reports, 2015, 5, 8529.	1.6	143
7	Abrogation of Akt signaling by Isobavachalcone contributes to its anti-proliferative effects towards human cancer cells. Cancer Letters, 2010, 294, 167-177.	3.2	80
8	Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. Cancer Cell, 2019, 35, 916-931.e9.	7.7	70
9	SIRT2 and lysine fatty acylation regulate the transforming activity of K-Ras4a. ELife, 2017, 6, .	2.8	70
10	Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2. Blood, 2018, 131, 2698-2711.	0.6	66
11	SIRT6 regulates Ras-related protein R-Ras2 by lysine defatty-acylation. ELife, 2017, 6, .	2.8	62
12	Selective blockade of the lyso-PS lipase ABHD12 stimulates immune responses in vivo. Nature Chemical Biology, 2018, 14, 1099-1108.	3.9	55
13	Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All- <i>trans</i> -Retinoic Acid-Induced Differentiation by Modifying the RAR α /STAT1 Axis. Molecular Cancer Therapeutics, 2013, 12, 195-206.	1.9	38
14	Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity-Dependent Inhibition, and On-Target Anticancer Activities. ChemMedChem, 2018, 13, 1890-1894.	1.6	38
15	Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Reports, 2021, 37, 109957.	2.9	38
16	A Small-Molecule SIRT2 Inhibitor That Promotes K-Ras4a Lysine Fatty-Acylation. ChemMedChem, 2019, 14, 744-748.	1.6	36
17	MEK/ERK Dependent Activation of STAT1 Mediates Dasatinib-Induced Differentiation of Acute Myeloid Leukemia. PLoS ONE, 2013, 8, e66915.	1.1	35
18	Simultaneous Inhibition of SIRT2 Deacetylase and Defatty-Acylase Activities via a PROTAC Strategy. ACS Medicinal Chemistry Letters, 2020, 11, 2305-2311.	1.3	29

#	ARTICLE	IF	CITATIONS
19	Discovery and Optimization of Selective and in Vivo Active Inhibitors of the Lysophosphatidylserine Lipase β -Hydrolase Domain-Containing 12 (ABHD12). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1643-1656.	2.9	27
20	Comparative Nucleotide-Dependent Interactome Analysis Reveals Shared and Differential Properties of KRas4a and KRas4b. <i>ACS Central Science</i> , 2018, 4, 71-80.	5.3	25
21	SIRT2 and Lysine Fatty Acylation Regulate the Activity of RalB and Cell Migration. <i>ACS Chemical Biology</i> , 2019, 14, 2014-2023.	1.6	25
22	Blockade of the Lysophosphatidylserine Lipase ABHD12 Potentiates Ferroptosis in Cancer Cells. <i>ACS Chemical Biology</i> , 2020, 15, 871-877.	1.6	25
23	The ubiquitin-proteasome pathway plays essential roles in ATRA-induced leukemia cells G ₀ /G ₁ phase arrest and transition into granulocytic differentiation. <i>Cancer Biology and Therapy</i> , 2010, 10, 1157-1167.	1.5	23
24	The Spastic Paraplegia-Associated Phospholipase DDHD1 Is a Primary Brain Phosphatidylinositol Lipase. <i>Biochemistry</i> , 2018, 57, 5759-5767.	1.2	22
25	Phospholipase β 2 regulates endocannabinoid and eicosanoid networks in innate immune cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	15
26	Involvement of mitogen-activated protein kinase in signal transducer and activator of transcription-mediated differentiation induced by bortezomib in acute myeloid leukemia cells. <i>Molecular Carcinogenesis</i> , 2013, 52, 18-28.	1.3	8
27	Lessons learned from a SIRT2-selective inhibitor. <i>Oncotarget</i> , 2016, 7, 22971-22972.	0.8	2